Case Report Open Access
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2014; 20(25): 8288-8291
Published online Jul 7, 2014. doi: 10.3748/wjg.v20.i25.8288
Novel therapy for non-cirrhotic hyperammonemia due to a spontaneous splenorenal shunt
Shari S Rogal, Angela Hu, Rupal Bandi, Obaid Shaikh
Shari S Rogal, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, United States
Angela Hu, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States
Rupal Bandi, Department of Radiology, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA 15240, United States
Obaid Shaikh, Division of Gastroenterology, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA 15240, United States
Author contributions: All authors contributed to writing and editing the manuscript.
Supported by Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development
Correspondence to: Shari S Rogal, MD, MPH, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, 200 Lothrop Street, M Level, C Wing, PUH, Pittsburgh, PA 15213, United States. rogalss@upmc.edu
Telephone: +1-412-6489115 Fax: +1-412-6489378
Received: October 2, 2013
Revised: December 10, 2013
Accepted: January 14, 2014
Published online: July 7, 2014

Abstract

Spontaneous splenorenal shunts in the absence of cirrhosis have rarely been reported as a cause hyperammonemia with encephalopathy. Several closure techniques of such lesions have been described. Here we report a case of a patient with no history of liver disease who developed significant confusion. After an extensive workup, he was found to have hyperammonemia and encephalopathy due to formation of a spontaneous splenorenal shunt. There was no evidence of cirrhosis on biopsy or imaging and no portal hypertension when directly measured. The shunt was 18 mm and too large for embolization so the segment of the splenic vein between the portal vein and the shunt was occluded using an Amplatzer plug. Thus, the superior mesenteric flow was directed entirely to the liver. After interventional radiology closure of the shunt using this technique there was complete resolution of symptoms. The case represents the first report of a successful closure of splenorenal shunt via percutaneous embolization of the splenic vein with an amplatzer plug using a common femoral vein approach.

Key Words: Splenorenal shunt, Gastric bypass, Hyperammonemia, Encephalopathy

Core tip: This is the first reported case of non-portal hypertension associated hepatic encephalopathy related to a large splenorenal shunt that was successfully closed percutaneously with an Amplatzer plug applied to the splenic vein.



INTRODUCTION

Splenorenal shunts are a rare cause of hyperammonemia and encephalopathy in the absence of cirrhosis[1]. This vascular phenomenon has mostly been reported in patients with cirrhosis and is thought to be due to elevations in levels of angiogenic factors[2]. Most reported cases of splenorenal shunts have been treated with either surgery or, rarely, percutaneous transhepatic embolization[1,3]. This case represents the first report of the successful closure of a spleno-renal shunt via percutaneous embolization of the splenic vein with an Amplatzer plug.

CASE REPORT

A 58-year-old man with a history of gastric bypass surgery presented to the Veterans Affairs Medical Center with 4 mo of confusion. The confusion was described as episodic, worst in the mornings, and lasting up to 24-48 h. The episodes were severe and associated with violent behavior, resulting in the loss of his job. His initial workup at another hospital was significant only for hyperammonemia, so he was prescribed lactulose and rifaximin. He reported 4 bowel movements per day on this regimen, but despite adherence he continued to have episodes of confusion with 5 hospitalizations in 3 mo.

His past medical history was notable for obesity for which he underwent Roux-en-Y gastric bypass in 2006 with weight decrease from 356 to 180 pounds. He had been recently diagnosed with schizoaffective disorder and panic disorder due to his episodes of confusion. He also had diet-controlled diabetes, and hypothyroidism. He had undergone a cholecystectomy, panniculectomy, and mastopexy. He took no over-the-counter medications or herbal medications and had no known drug allergies. He lived with his wife and had 4 children. He had no history of alcohol, tobacco, or drug use. He had no history of travel, tattoos, or prior transfusions. His family history was notable for a mother with obesity and diabetes but no hepatic, gastrointestinal, or psychiatric illnesses.

On physical exam he was afebrile with a heart rate of 80 beats per minute, blood pressure of 110/75 mmHg, respiratory rate of 16 breaths per minute, and oxygen saturation of 100% on room air. He weighed 180 pounds and stood 5 foot 11 inches tall, giving him a body mass index of 25. His exam was notable for a calm demeanor, normal cardiopulmonary exam, and abdomen without hepatosplenomegaly, tenderness, distention, caput medusae, or dullness at the flanks. He had no peripheral edema. He was alert and oriented to person, place, date, and situation and had no asterixis. His skin exam was without spider angiomata or palmar erythema.

His laboratory values were notable for a glucose 71 mg/dL, WBC 6.2 × 109/L, hemoglobin 13.6 mg/dL, platelets 101 × 109/L, AST 33 IU/L, ALT 23 IU/L, Alkaline phosphatase 32 IU/L, total bilirubin 0.8 mg/dL (direct 0.2 mg/dL), GGT 11 IU/L, albumin 3.8 mg/dL, thyroid stimulating hormone 2.3 uIU/L, and INR 1.0. His venous ammonia was notably typically between 50 and 150 μmol/L but reached a maximum of 306 μmol/L. His symptom severity correlated with his ammonia level, and typically he was symptomatic with an ammonia level above 80. Amino acid testing yielded low threonine, glutamic acid, alanine, valine, isoleucine, leucine, and lysine, but a high level of glutamine.

His brain MRI did not demonstrate any intracranial abnormalities. An EEG during one episode demonstrated diffuse generalized slowing suggestive of minimal encephalopathy. A liver biopsy demonstrated no abnormalities. CT of his abdomen demonstrated a normal appearing liver and a large splenorenal shunt adjacent to clips from the prior abdominal surgery. There was no radiographic evidence of portal hypertension. An upper endoscopy revealed no gastric or esophageal varices and no portal hypertensive gastropathy.

The decision was made to attempt percutaneous closure of the splenorenal shunt. Ultrasound guided access into the right common femoral vein was obtained. The left renal vein was selectively catheterized. Then, access via the splenorenal shunt into the portal vein was obtained. Pressure in the portal vein was measured as 5 mmHg and the right atrial pressure was 4 mmHg. Portal venography demonstrated patent superior mesenteric (SMV) and portal veins (Figure 1). The majority of the SMV flow was diverted through the splenorenal shunt into the renal vein (systemic circulation) causing hyperammonemia. A 7 French sheath was advanced through the shunt. A 20 mm Amplatzer plug was deployed in the splenic vein segment between the main portal vein and splenorenal shunt (Figures 1 and 2). Subsequent angiograms demonstrated that the entire SMV flow was directed towards the liver and the entire splenic vein flow was directed via the splenorenal shunt into the left renal vein. After this procedure he had complete resolution of his symptoms. His ammonia level at follow-up 2 mo later was 19.

Figure 1
Figure 1 Angiographic images of the splenorenal shunt before (panel A) and after (panel B) intervention.
Figure 2
Figure 2 Schematic of the vascular anatomy. SMV: Superior mesenteric.
DISCUSSION

This is a case of a 58 year old non-cirrhotic man who developed severe confusion and hyperammonemia in the setting of a spontaneous splenorenal shunt. This was successfully treated with using percutaneous closure with an Amplatzer plug via femoral approach in a non-cirrhotic patient. This case is novel in that it presents a novel therapy for a debilitating problem.

The pressure gradient between the right atrium and portal vein was minimal indicating that portal hypertension was not a factor in this case. This was also confirmed by the non-cirrhotic liver biopsy and lack of evidence of portal hypertension on imaging, endoscopy, or physical exam. The large size of the splenorenal shunt (18 mm) would require a large (e.g., 26 mm) closure device which is not commercially available. This type of device would carry a high risk of embolization into the pulmonary circulation if a smaller size was used. The segment of splenic vein between the portal vein and the shunt was only 12 mm. This segment was thus easier and safer to occlude. Occlusion with a 20 mm plug allowed SMV flow to be directed entirely towards the liver. The splenic vein flow was directed into systemic circulation via a more distal spleno-renal shunt but this was not clinically significant.

One interesting aspect of this case is the close proximity of the splenorenal shunt to the site of gastric bypass clips. The gastric bypass surgery was standard and there were no vascular complications. The splenorenal shunt was located in a common site and there is no reason to believe there was a mechanical cause (e.g., inadvertent clamp injury) to cause the formation of the shunt. However, gastric bypass has been rarely associated with subsequent development of hyperammonemic encephalopathy. A 2008 case series found several women with no history of liver disease who presented with mental status changes 0.3-28 years after Roux-en-Y gastric bypass[4]. All patients died despite agressive treatment and the authors hypothesized that hyperinsulinemia and zinc deficiency post-bypass decreased expression and function of ornithine transcarbamoylase (OTC), unmasking partial previously clinically silent X-linked OTC deficiencies. Another published link between gastric bypass and hyperammonemia is carnitine deficiency[5].

Only a few cases of splenorenal shunts have been reported in the absence of chronic liver disease[2,6]. One group in Japan did a nation-wide search for non-cirrhotic portal-systemic encephalopathy[1]. They found 47 cases, and five types of portosystemic shunts were identified in patients with no history of liver disease: intrahepatic, intra- to extra-hepatic, extrahepatic, extrahepatic with idiopathic portal hypertension, and congenitally absent portal vein. In this case series, 23 patients (49%) developed extrahepatic shunts such as the splenorenal shunt described here. These shunts were either clinically silent or presented insidiously as psychiatric disease, as in the case of our patient. Precipitants of encephalopathic episodes were described as similar to traditional hepatic encephalopathy and an increased incidence with age was attributed to increased ammonia sensitivity and decreased liver function associated with aging.

Treatment of splenorenal shunts has included a variety of modalities including closure with a metal coil, surgical ligation, balloon occluded retrograde transvenous obliteration, and shunt-preserving disconnection of the portal and systemic circulation[1]. Another study in 1997 by Sakurbayashi assessed 7 patients with cirrhosis and encephalopathy attributed to spontaneous splenorenal shunts and found coiling to be successful in treating the shunts when technically possible (i.e., not limited by high portal pressures)[3]. They found that a percutaneous transhepatic embolization was effective in 3 of 4 patients and a transrenal in 1 of 3 patients. To our knowledge, percutaneous embolization of the splenic vein with an Amplatzer plug through a transrenal approach in this setting has never been reported. This percutaneous retrograde technique described here thus represents another option for the treatment of splenorenal shunts. Advantages include a minimally invasive approach with minimal potential complications. Successful percutaneous closure of splenorenal shunts using Amplatzer plugs in the splenic vein can be considered a possible alternative to riskier embolization procedures in patients with large shunts and non-cirrhotic livers. Splenorenal shunts are a rare cause of debilitating encephalopathy due to hyperammonemia. This case presents a novel, minimally invasive treatment option for a confusing cause of confusion.

ACKNOWLEDGMENTS

The contents do not represent the views of the Department of Veterans Affairs or the United States Government.

COMMENTS
Case characteristics

This is a 58-year-old-man with a history of roux-en-Y gastric bypass who presented with severe confusion.

Clinical diagnosis

He was found to severely encephalopathic with asterixis and no findings of chronic liver disease.

Differential diagnosis

The differential diagnosis included cirrhosis, renal disease, metabolic derangements, and vascular shunting.

Laboratory diagnosis

Laboratory testing demonstrated hyperammonemia that corresponded to his level of confusion.

Imaging diagnosis

He was found to have a large splenorenal shunt on computed tomography scan.

Pathological diagnosis

A liver biopsy demonstrated that he had no underlying liver disease.

Treatment

The percutaneous placement of an Amplatzer plug into the splenic vein segment between the main portal vein and the splenorenal shunt, resulting in complete symptom resolution.

Related reports

A manuscript by Watanabe et al reviews a nation-wide experience with evaluation and treatment of portosystemic shunts in non-cirrhotic patients.

Term explanation

An Amplatzer plug is a permanent occluding, self-expanding, flexible metallic device built with nitinol braids that is an alternative to coils or balloon occlusion.

Experiences and lessons

The case represents the first report of a successful closure of spleno-renal shunt via percutaneous embolization of the splenic vein with an Amplatzer plug using a common femoral vein approach.

Peer review

Though the presence of a spontaneous splenorenal shunt is not novel in and of itself, this case illustrates the effectiveness of a novel technique of a minimally-invasive cure for a debilitating condition.

Footnotes

P- Reviewers: Iacono C, Wang DR S- Editor: Qi Y L- Editor: A E- Editor: Wang CH

References
1.  Watanabe A. Portal-systemic encephalopathy in non-cirrhotic patients: classification of clinical types, diagnosis and treatment. J Gastroenterol Hepatol. 2000;15:969-979.  [PubMed]  [DOI]  [Cited in This Article: ]
2.  Chen JS, Chuang SC, Wang SN, Chang WT, Kuo KK, Lee KT, Ker CG. Natural course of splenic artery aneurysm with associated spontaneous splenorenal shunt in non-cirrhotic liver: an 18-year observational follow-up and review of literature. Kaohsiung J Med Sci. 2013;29:55-58.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Sakurabayashi S, Sezai S, Yamamoto Y, Hirano M, Oka H. Embolization of portal-systemic shunts in cirrhotic patients with chronic recurrent hepatic encephalopathy. Cardiovasc Intervent Radiol. 1997;20:120-124.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Fenves A, Boland CR, Lepe R, Rivera-Torres P, Spechler SJ. Fatal hyperammonemic encephalopathy after gastric bypass surgery. Am J Med. 2008;121:e1-e2.  [PubMed]  [DOI]  [Cited in This Article: ]
5.  Limketkai BN, Zucker SD. Hyperammonemic encephalopathy caused by carnitine deficiency. J Gen Intern Med. 2008;23:210-213.  [PubMed]  [DOI]  [Cited in This Article: ]
6.  Cacciapaglia F, Vadacca M, Coppolino G, Buzzulini F, Rigon A, Zennaro D, Zardi E, Afeltra A. Spontaneous splenorenal shunt in a patient with antiphospholipid syndrome: the first case reported. Lupus. 2007;16:56-58.  [PubMed]  [DOI]  [Cited in This Article: ]